Business
TELA Bio Announces U.S. Commercial Launch of NIVIS™ Fibrillar Collagen Pack, The Natural Restoration Solution to Support Healing of Surgical Wounds
Company grows product portfolio, expanding product offerings to optimize soft tissue preservation and restoration MALVERN, Pa., Jan. 09, 2023 (GLOBE NEWSWIRE)
About this update from Tela Bio, Inc.
[{"type":"text","content":"Company grows product portfolio, expanding product offerings to optimize soft tissue preservation and restoration\nMALVERN, Pa., Jan. 09, 2023 (GLOBE NEWSWIRE) -- TELA Bio, Inc. (NASDAQ: TELA), a commercial-stage medical technology company focused on providing innovative technologies that optimize clinical outcomes by prioritizing the preservation and restoration of the patient’s own anatomy, today announced the commercial launch of its NIVIS Fibrillar Collagen Pack. NIVIS Fibrillar Collagen Pack is an absorbent matrix of Type I and Type III bovine collagen designed to manage moderately to heavily exudating wounds and to control minor bleeding. Type I and Type III collagen closely resemble the native collagen of a patient and have been shown to stimulate cellular activity and contribute to new tissue development. Specifically, Type III collagen helps control wound contraction and the amount of scar deposition during wound healing. NIVIS is provided in particulate form allowing it to be molded and packed into wounds facilitating contact with host tissue. “Surgical wound management can be a source of concern, especially in patients considered higher risk for complications,” said Dr. Michael Sawyer, General Surgeon at Comanche County Memorial Hospital. “While there are various options to treat these patients, I’m encouraged by both the handling and initial clinical utility I’ve experienced with NIVIS.” In April 2022, TELA Bio entered an exclusive development and distribution partnership for Collagen Matrix, Inc.’s proprietary fibrillar collagen pack in the USA. NIVIS Fibrillar Collagen Pack builds on TELA Bio’s soft-tissue preservation and restoration mission which prioritizes leveraging the patient’s natural healing response. “The commercial launch of NIVIS is a meaningful step forward in our commitment to provide a suite of effective soft tissue repair solutions for our growing customer base in general, and plastics and reconstructive surgery,” said Antony Koblish, President and CEO of TELA Bio. “NIVIS is a high-quality product that complements our OviTex® portfolio perfectly and provides a new vehicle of growth for the company.” About TELA Bio, Inc. TELA Bio, Inc. (NASDAQ: TELA) is a commercial-stage medical technology company focused on providing innovative technologies that optimize clinical outcomes by prioritizing the preser...